A Phase 1b/2 Study of PF-07220060 in Combination with PF-07104091 Plus Endocrine Therapy in Participants with BC and other Advanced Solid Tumors
Excerpt:
...• Male and female participants ≥18 years of age at Visit 1.• Histological or cytological diagnosis of locally advanced or metastatic solid tumor/diagnosis which is unresectable.• Evaluable lesion (including skin or bone lesion only, Part 1)• Participants entering the study in the expansion cohort have at least 1 measurable lesion as defined by RECIST (version 1.1) that has not been previously irradiated.• Cancer type: • HR-positive HER2-negative tumor (Part 1 and Part 2) • HR-positive HER2-positive tumor (Part 1) • Advanced solid tumor or metastatic disease (Part 1) • ECOG PS 0 or 1....